NO135709B - - Google Patents
Download PDFInfo
- Publication number
- NO135709B NO135709B NO3949/72A NO394972A NO135709B NO 135709 B NO135709 B NO 135709B NO 3949/72 A NO3949/72 A NO 3949/72A NO 394972 A NO394972 A NO 394972A NO 135709 B NO135709 B NO 135709B
- Authority
- NO
- Norway
- Prior art keywords
- kallikrein
- solution
- components
- ammonium
- eluate
- Prior art date
Links
- 102000001399 Kallikrein Human genes 0.000 claims description 96
- 108060005987 Kallikrein Proteins 0.000 claims description 96
- 239000000243 solution Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 14
- 239000005695 Ammonium acetate Substances 0.000 claims description 14
- 229940043376 ammonium acetate Drugs 0.000 claims description 14
- 235000019257 ammonium acetate Nutrition 0.000 claims description 14
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 7
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 4
- XJMWHXZUIGHOBA-UHFFFAOYSA-N azane;propanoic acid Chemical compound N.CCC(O)=O XJMWHXZUIGHOBA-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- -1 diethylaminoethyl groups Chemical group 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000012266 salt solution Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical group CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000013078 crystal Substances 0.000 description 10
- 239000012507 Sephadex™ Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 239000000337 buffer salt Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RSYYQCDERUOEFI-JTQLQIEISA-N N-benzoyl-L-arginine Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-JTQLQIEISA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100025421 Serine protease inhibitor Kazal-type 6 Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19712154556 DE2154556C3 (de) | 1971-11-03 | 1971-11-03 | Verfahren zur Herstellung von kristallinen Kallidinogenase-(Kallikrein)-Komponenten A und B und Arzneimittel mit einem Gehalt an einer dieser Komponenten |
| DE2154557A DE2154557C3 (de) | 1971-11-03 | 1971-11-03 | Verfahren zur Herstellung von hochreiner Kallidinogenase (Kallikrein) und ein die danach erhaltene kristalline Kallidinogenase enthaltendes Arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135709B true NO135709B (xx) | 1977-02-07 |
| NO135709C NO135709C (xx) | 1977-05-16 |
Family
ID=25761980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO3949/72A NO135709C (xx) | 1971-11-03 | 1972-11-01 |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS5716794B2 (xx) |
| AT (1) | AT319466B (xx) |
| AU (1) | AU463125B2 (xx) |
| BE (1) | BE790794A (xx) |
| CA (1) | CA989334A (xx) |
| CH (1) | CH584547A5 (xx) |
| DD (1) | DD103907A5 (xx) |
| DK (1) | DK131893C (xx) |
| EG (1) | EG10631A (xx) |
| ES (1) | ES408158A1 (xx) |
| FI (1) | FI51203C (xx) |
| FR (1) | FR2158519B1 (xx) |
| GB (1) | GB1384335A (xx) |
| HU (1) | HU164371B (xx) |
| IE (1) | IE37127B1 (xx) |
| IL (1) | IL40715A (xx) |
| LU (1) | LU66403A1 (xx) |
| NL (1) | NL7214730A (xx) |
| NO (1) | NO135709C (xx) |
| PL (1) | PL85201B1 (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5951222A (ja) * | 1982-09-17 | 1984-03-24 | Wakamoto Pharmaceut Co Ltd | 安定なカリジノゲナ−ゼ製剤 |
| JPS59205312A (ja) * | 1982-12-28 | 1984-11-20 | Shunichi Naito | カリクレインの経直腸用吸収剤型 |
| JPS59137417A (ja) * | 1983-01-28 | 1984-08-07 | Morinaga Milk Ind Co Ltd | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 |
| JPH05163158A (ja) * | 1991-12-13 | 1993-06-29 | Sanwa Kagaku Kenkyusho Co Ltd | 人尿性キニノゲナーゼを有効成分とする皮膚潰瘍の予防及び治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE910580C (de) * | 1952-08-26 | 1954-05-03 | Bayer Ag | Verfahren zur Gewinnung des Kreislaufhormons Kallikrein |
| FR1284825A (fr) * | 1960-03-25 | 1962-02-16 | Bayer Ag | Procédé de fabrication de préparations de kallikréine extrêment purifiées |
-
0
- BE BE790794D patent/BE790794A/xx unknown
-
1972
- 1972-10-16 CH CH1507772A patent/CH584547A5/xx not_active IP Right Cessation
- 1972-10-27 JP JP10726172A patent/JPS5716794B2/ja not_active Expired
- 1972-10-31 LU LU66403A patent/LU66403A1/xx unknown
- 1972-10-31 NL NL7214730A patent/NL7214730A/xx not_active Application Discontinuation
- 1972-10-31 AT AT926072A patent/AT319466B/de not_active IP Right Cessation
- 1972-10-31 ES ES408158A patent/ES408158A1/es not_active Expired
- 1972-11-01 FI FI723041A patent/FI51203C/fi active
- 1972-11-01 HU HUBA2822A patent/HU164371B/hu unknown
- 1972-11-01 IL IL40715A patent/IL40715A/xx unknown
- 1972-11-01 NO NO3949/72A patent/NO135709C/no unknown
- 1972-11-01 CA CA155,331A patent/CA989334A/en not_active Expired
- 1972-11-01 DD DD166618A patent/DD103907A5/xx unknown
- 1972-11-02 DK DK544172A patent/DK131893C/da active
- 1972-11-02 EG EG453/72A patent/EG10631A/xx active
- 1972-11-02 GB GB5055972A patent/GB1384335A/en not_active Expired
- 1972-11-02 PL PL1972158590A patent/PL85201B1/pl unknown
- 1972-11-02 IE IE1487/72A patent/IE37127B1/xx unknown
- 1972-11-02 AU AU48469/72A patent/AU463125B2/en not_active Expired
- 1972-11-03 FR FR7239035A patent/FR2158519B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2158519A1 (xx) | 1973-06-15 |
| ES408158A1 (es) | 1975-11-16 |
| FI51203C (fi) | 1976-11-10 |
| AU463125B2 (en) | 1975-07-17 |
| DD103907A5 (xx) | 1974-02-12 |
| GB1384335A (en) | 1975-02-19 |
| CA989334A (en) | 1976-05-18 |
| EG10631A (en) | 1976-08-31 |
| IE37127B1 (en) | 1977-05-11 |
| AT319466B (de) | 1974-12-27 |
| AU4846972A (en) | 1974-05-02 |
| JPS4856889A (xx) | 1973-08-09 |
| DK131893C (da) | 1976-02-16 |
| NL7214730A (xx) | 1973-05-07 |
| HU164371B (xx) | 1974-02-28 |
| IL40715A0 (en) | 1973-01-30 |
| JPS5716794B2 (xx) | 1982-04-07 |
| NO135709C (xx) | 1977-05-16 |
| FI51203B (xx) | 1976-08-02 |
| FR2158519B1 (xx) | 1976-04-23 |
| DK131893B (da) | 1975-09-22 |
| IE37127L (en) | 1973-05-03 |
| PL85201B1 (xx) | 1976-04-30 |
| LU66403A1 (xx) | 1973-01-23 |
| BE790794A (fr) | 1973-04-30 |
| CH584547A5 (xx) | 1977-02-15 |
| IL40715A (en) | 1975-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0317376B1 (fr) | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques | |
| FR2461500A1 (fr) | Procede de production d'une substance capable de stimuler la proliferation et la differenciation des cellules souches granulopoietiques humaines | |
| Chow et al. | Bovine pepsinogen and pepsin: I. Isolation, purification, and some properties of the pepsinogen | |
| CN105153297B (zh) | 一种从Cohn组分Ⅳ沉淀中分离纯化α2-巨球蛋白的方法 | |
| DK141274B (da) | Fremgangsmåde til isolering af blodkoagulationsfaktorerne. | |
| US4170590A (en) | Ion exchanger treatment of citrate-stabilized plasma | |
| DE3228502A1 (de) | Verfahren zur herstellung des c1-inaktivators und seine verwendung | |
| JPS62138434A (ja) | アルフア−１−プロテイナ−ゼ阻害剤の製造法 | |
| JPS59137417A (ja) | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 | |
| Pope et al. | The preparation of diphtheria antitoxin in a state of high purity | |
| JPH0381290A (ja) | 精製されたアルブミン溶液の製造方法 | |
| Green | [73] Purification of avidin | |
| NO135709B (xx) | ||
| US2808362A (en) | Preparation of hyaluronidase | |
| Miller | Rivanol, resin and the isolation of thrombins | |
| US3905870A (en) | Purification of kallikrein | |
| US4027012A (en) | Process for the extraction of components having anticoagulant activity "in vivo" from snake venoms and products obtained | |
| US3677901A (en) | Process for the production of glycerokinase | |
| JPS6160050B2 (xx) | ||
| DE2154557C3 (de) | Verfahren zur Herstellung von hochreiner Kallidinogenase (Kallikrein) und ein die danach erhaltene kristalline Kallidinogenase enthaltendes Arzneimittel | |
| Makinen et al. | Studies on the formation of aminopeptidase-like enzymes in regenerating wound tissue | |
| CN110563833A (zh) | 一种人血白蛋白标准物质原料的制备方法及其产品和应用 | |
| US3036960A (en) | Method of isolating and purifying a protease from aspergillus | |
| RU2799637C1 (ru) | Способ получения биологически активного пептидно-аминокислотного препарата на основе плазмы крови человека | |
| SU482934A3 (ru) | Способ очистки калликреина |